-

07:07:11 AM

Latest EBS Stock Market News

EBS - Emergent Biosolutions Inc

09/21/21 1:23 PM

NYSE : EBS

Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.

In April 2020, the U.S. Food and Drug Administration conducted an inspection which revealed serious problems, including deficient containment areas, necessary technology and personnel upgrades, and inadequate employee training. On March 31, 2021, media reports revealed that ingredients for the J&J and AstraZeneca vaccines were“ mixed up” at the Baltimore...

RHEA-AI

very negative

09/14/21 8:00 AM

NYSE : EBS

covid-19

Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

Emergent BioSolutions Inc. (NYSE:EBS) and Providence Therapeutics

RHEA-AI

positive

08/25/21 6:30 AM

NYSE : EBS

clinical trialcovid-19

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19

NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), for potential treatment of COVID-19 in adult patients at risk of progression to severe disease GAITHERSBURG, Md., Aug.

RHEA-AI

neutral

08/23/21 4:05 PM

NYSE : EBS

conferences

Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Three Part Advisors IDEAS Midwest Conference August 25-26, 2021 Pre-recorded

RHEA-AI

neutral

07/29/21 4:05 PM

NYSE : EBS

earnings

Emergent BioSolutions Reports Financial Results For Second Quarter 2021

Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021. “Our second quarter performance demonstrates the strength of our

RHEA-AI

positive

07/29/21 7:24 AM

NYSE : EBS

covid-19

Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance.

RHEA-AI

neutral

07/26/21 9:01 AM

NYSE : EBS

Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use

Emergent BioSolutions joins forces with an alliance of advocacy organizations that share a common goal to empower open communication and address the stigma of opioid overdoses, which are oftentimes accidental. Professional football player Darren Waller and lifestyle influencer Dani Schaffer openly

RHEA-AI

negative

07/15/21 6:30 AM

NYSE : EBS

earnings

Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third

RHEA-AI

neutral

06/11/21 4:35 PM

NYSE : EBS

covid-19

COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization

Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19

RHEA-AI

neutral

05/26/21 6:30 AM

NYSE : EBS

clinical trial

Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate

A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19 times higher than pre-vaccination titers following a single adjuvanted 40 µg dose reflecting

RHEA-AI

neutral

EBS Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.emergentbiosolutions.com
CeoRobert Kramer
Security nameEmergent Biosolutions Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees2200
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address400 Professional Dr Ste 400
StateMaryland
CityGaithersburg
Zip20879-3457
CountryUS
Phone12406313200

EBS Description:

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through their specialty products and contract development and manufacturing services, the company is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent BioSolutions aims to build healthier and safer communities. The company aspires to deliver peace of mind to theis patients and customers so they can focus on what's most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030.